Susan Acton
Neuroinflammation Research Head Adiso Therapeutics
Dr. Acton has dedicated her career to advancing research in neurodegenerative and cardiovascular diseases through the identification of novel drug targets. She possesses deep expertise in elucidating key proteins within critical biological pathways and has made seminal contributions, including the discovery of the HDL cholesterol receptor (SR-BI) and ACE2. Additionally, she has successfully led the Neuro ADS024 LPAR3 preclinical program from its inception.
Seminars
Friday 12th December 2025
Harnessing LPAR3 as a Novel Approach to Transform Alzheimer’s & Neurodegenerative Disease Treatment
2:00 pm
- Unlocking the therapeutic promise of ADS024, a single-strain, orally delivered live biotherapeutic product, by demonstrating efficacy across Alzheimer’s and multiple neuroinflammatory and neurodegenerative disease models through LPAR3 agonism
- Exploring the gut–brain axis with a focus on ADS024’s impact on neuroinflammation, gut-derived signalling, and implications for disease progression
- Positioning LPAR3 as an underexplored GPCR target within the EDG/S1P receptor family, with genetic ties to Alzheimer’s biomarkers and strong potential for novel, accessible neuroinflammation therapies
